ReviewDiagnostics (Basel, Switzerland)2026
Diagnostic Method Advancement to Improve the Prognosis of Pancreatic Ductal Adenocarcinoma.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, and early diagnosis is essential for improving patient outcomes. Conventional imaging modalities such as ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) have limitations in detecting small PDAC. Endoscopic ultrasonography (EUS) is useful for identifying small lesions; however, even small PDAC can be invasive and may metastasize, resulting in Stage IV disease. The most effective way to improve the prognosis of PDAC is to diagnose lesions confined to the ductal epithelium, such as high-grade pancreatic intraepithelial neoplasia (HG-PanIN) or carcinoma in situ (CIS). Identifying focal pancreatic parenchymal atrophy (FPPA) on CT or MRI may suggest the presence of HG-PanIN/CIS and prompt further evaluation using serial pancreatic juice aspiration cytologic examination (SPACE). Recognizing FPPA and performing SPACE enables the diagnosis of PDAC at Stage 0 (HG-PanIN/CIS), which can lead to improved prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.